BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32699577)

  • 1. Structure and function of Septin 9 and its role in human malignant tumors.
    Sun J; Zheng MY; Li YW; Zhang SW
    World J Gastrointest Oncol; 2020 Jun; 12(6):619-631. PubMed ID: 32699577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Septin 9_i2 is downregulated in tumors, impairs cancer cell migration and alters subnuclear actin filaments.
    Verdier-Pinard P; Salaun D; Bouguenina H; Shimada S; Pophillat M; Audebert S; Agavnian E; Coslet S; Charafe-Jauffret E; Tachibana T; Badache A
    Sci Rep; 2017 Mar; 7():44976. PubMed ID: 28338090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Septin 9 (MSF) gene is amplified and overexpressed in mouse mammary gland adenocarcinomas and human breast cancer cell lines.
    Montagna C; Lyu MS; Hunter K; Lukes L; Lowther W; Reppert T; Hissong B; Weaver Z; Ried T
    Cancer Res; 2003 May; 63(9):2179-87. PubMed ID: 12727837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis.
    Song L; Yu H; Jia J; Li Y
    Cancer Biomark; 2017; 18(4):425-432. PubMed ID: 28128742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging of hypoxia-inducible factor 1α and septin 9 interaction by bimolecular fluorescence complementation in live cancer cells.
    Golan M; Mabjeesh NJ
    Oncotarget; 2017 May; 8(19):31830-31841. PubMed ID: 28380438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Properties of SEPT9 isoforms and the requirement for GTP binding.
    Robertson C; Church SW; Nagar HA; Price J; Hall PA; Russell SE
    J Pathol; 2004 May; 203(1):519-27. PubMed ID: 15095474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted knockdown of SEPT9_v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway.
    Amir S; Golan M; Mabjeesh NJ
    Mol Cancer Res; 2010 May; 8(5):643-52. PubMed ID: 20407014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of
    Sun J; Fei F; Zhang M; Li Y; Zhang X; Zhu S; Zhang S
    BMC Cancer; 2019 May; 19(1):450. PubMed ID: 31088406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
    Ladabaum U; Allen J; Wandell M; Ramsey S
    Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Septin Mutations in Human Cancers.
    Angelis D; Spiliotis ET
    Front Cell Dev Biol; 2016; 4():122. PubMed ID: 27882315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and cell biological characterization of a mammalian septin, Sept11.
    Hanai N; Nagata K; Kawajiri A; Shiromizu T; Saitoh N; Hasegawa Y; Murakami S; Inagaki M
    FEBS Lett; 2004 Jun; 568(1-3):83-8. PubMed ID: 15196925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Septin 9 Exhibits Polymorphic Binding to F-Actin and Inhibits Myosin and Cofilin Activity.
    Smith C; Dolat L; Angelis D; Forgacs E; Spiliotis ET; Galkin VE
    J Mol Biol; 2015 Oct; 427(20):3273-3284. PubMed ID: 26297986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study.
    Ørntoft MB; Nielsen HJ; Ørntoft TF; Andersen CL;
    BMC Cancer; 2015 Oct; 15():819. PubMed ID: 26514170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients.
    Tóth K; Patai ÁV; Kalmár A; Barták BK; Nagy ZB; Galamb O; Wichmann B; Tulassay Z; Molnár B
    Pathol Oncol Res; 2017 Jul; 23(3):699-706. PubMed ID: 28035516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered expression of the septin gene, SEPT9, in ovarian neoplasia.
    Burrows JF; Chanduloy S; McIlhatton MA; Nagar H; Yeates K; Donaghy P; Price J; Godwin AK; Johnston PG; Russell SE
    J Pathol; 2003 Dec; 201(4):581-8. PubMed ID: 14648661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter hypermethylation of
    Branchi V; Schaefer P; Semaan A; Kania A; Lingohr P; Kalff JC; Schäfer N; Kristiansen G; Dietrich D; Matthaei H
    Clin Epigenetics; 2016; 8():133. PubMed ID: 27999621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood.
    Payne SR
    Epigenomics; 2010 Aug; 2(4):575-85. PubMed ID: 22121975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter methylation of SEPT9 as a potential biomarker for early detection of cervical cancer and its overexpression predicts radioresistance.
    Jiao X; Zhang S; Jiao J; Zhang T; Qu W; Muloye GM; Kong B; Zhang Q; Cui B
    Clin Epigenetics; 2019 Aug; 11(1):120. PubMed ID: 31426855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Septin 9 amplification and isoform-specific expression in peritumoral and tumor breast tissue.
    Connolly D; Hoang HG; Adler E; Tazearslan C; Simmons N; Bernard VV; Castaldi M; Oktay MH; Montagna C
    Biol Chem; 2014 Feb; 395(2):157-67. PubMed ID: 24127542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SEPT9: A Specific Circulating Biomarker for Colorectal Cancer.
    Song L; Li Y
    Adv Clin Chem; 2015; 72():171-204. PubMed ID: 26471083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.